The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03769987
Recruitment Status : Unknown
Verified December 2018 by Robert P Baughman, University of Cincinnati. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
15 Years to 100 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Advanced sarcoidosis is defined by the presence of one or more of the following features:
Advanced pulmonary disease as defined by one or more of the following
Symptomatic cardiac disease due to sarcoidosis by either MRI or PET scanning and
Symptomatic neurologic disease
Patients who have received third line therapy (anti-TNF antibodies, rituximab, or RCI)
Patients with diagnosis of sarcoidosis based on ATS/WASOG criteria 22
Age ≥ 18 years.
Life expectancy of at least 2 years.
Pulmonary function tests (spirometry) within one month of entry or willing to under pulmonary function testing on the day of study enrollment
Sarcoidosis as characterized as either advanced or non-advanced (see protocol for definition of advanced disease)
Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator
Inability to comply with the protocol and/or not willing or not available for follow-up assessments.
Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.